Danske Bank A S boosted its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 44.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,107,117 shares of the biopharmaceutical company’s stock after acquiring an additional 340,439 shares during the quarter. Danske Bank A S’s holdings in Royalty Pharma were worth $64,611,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in RPRX. Provenance Wealth Advisors LLC purchased a new position in shares of Royalty Pharma in the 3rd quarter valued at approximately $26,000. CoreCap Advisors LLC increased its holdings in shares of Royalty Pharma by 89.2% in the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 413 shares during the period. Bessemer Group Inc. raised its stake in shares of Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 282 shares during the last quarter. Root Financial Partners LLC purchased a new stake in shares of Royalty Pharma during the third quarter worth approximately $62,000. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in shares of Royalty Pharma during the third quarter worth approximately $63,000. 54.35% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Royalty Pharma
In other news, EVP Christopher Hite sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president directly owned 270,401 shares of the company’s stock, valued at $15,826,570.53. This trade represents a 27.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 208,252 shares of company stock worth $12,324,407 in the last quarter. 18.84% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
RPRX has been the subject of several recent research reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $66.00 price target on shares of Royalty Pharma in a report on Thursday, August 6th. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. TD Cowen boosted their price objective on shares of Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. Finally, Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $63.29.
View Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Price Performance
Shares of NASDAQ:RPRX opened at $69.31 on Monday. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77. The company has a market cap of $39.76 billion, a P/E ratio of 57.76, a PEG ratio of 1.37 and a beta of 0.36. Royalty Pharma PLC has a 52 week low of $37.31 and a 52 week high of $70.37. The company has a 50-day moving average price of $61.51 and a 200 day moving average price of $54.53.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma’s payout ratio is presently 78.33%.
Royalty Pharma Company Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Further Reading
- Five stocks we like better than Royalty Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
